Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

• Published in: Abdominal imaging Vol. 45; no. 11; pp. 3779 - 3788
• Main Authors: Barr, Richard G., Huang, Pintong, Luo, Yan, Xie, Xiaoyan, Zheng, Rongqin, Yan, Kun, Jing, Xiang, Luo, Yukun, Xu, Huixiong, Fei, Xiang, Lee, Jeong Min
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.11.2020; Springer Nature B.V
• Subjects: Ablation; Biopsy; Comparative studies; Contrast agents; Contrast media; Gastroenterology; Hepatology; Imaging; Liver; Liver diseases; Medicine; Medicine & Public Health; Radiology; Reagents; Review; Ultrasonic imaging; Ultrasound; Sonazoid; Liver; Sonovue (Lumason); Ultrasound contrast; CEUS
• ISSN: 2366-004X; 2366-0058; 2366-0058
• DOI: 10.1007/s00261-020-02573-9

Contrast-enhanced ultrasound (CEUS) has become an established modality in various clinical indications for liver diseases. SonoVue ® , a pure blood pure agent, and Sonazoid ® , which exhibits an additional Kupffer phase, are contrast agents approved for liver imaging. This review discusses and compares the current clinical evidence for these two ultrasound contrast agents in the characterization and detection of focal liver lesions in the non-cirrhotic and cirrhotic liver, as well as for the use in interventional procedures such as liver biopsy guidance, and local ablation treatment monitoring. Reference is made to clinical studies which evaluated the accuracy of CEUS using a standard of reference, its safety, or to comparative studies of these two agents.